Q3 2025 Nanoform Finland Oyj Earnings Call Transcript
Key Points
- Nanoform Finland PLC (FRA:4YL) received a commercial GMP manufacturing license, allowing them to produce APIs for products with marketing authorization in Europe and other global markets.
- The company has seen a significant increase in proposals sent, indicating growing interest in their technology from investors and generics companies.
- Nanoform's biologics technology is gaining strong market traction, particularly in high concentration subcutaneous injection and lung delivery of biologics.
- The company has expanded its market presence into Asia, establishing strong relationships in Japan and South Korea.
- Nanoform has maintained a strong balance sheet with almost EUR30 million in cash and aims for a cash burn below EUR10 million in 2026, indicating financial stability and strategic cost management.
- The funding situation for biotechs remains challenging, impacting the number of signings despite increased proposals.
- Large pharma companies are focusing on cost-cutting and reducing personnel, which affects early-stage pipeline development.
- The company is still in the early stages of generating significant milestone payments and top-line revenue.
- There are delays in decision-making within the industry, affecting the conversion of proposals into signed projects.
- The regulatory approval process for biosimilars has changed, increasing competition and potentially impacting Nanoform's market position.
Welcome to the conference call. (Operator Instructions)
Now I will hand the conference over to the speakers. Please go ahead.
Good afternoon all, and a warm welcome to Nanoform's third quarter 2025 report presentation. My name is Henri von Haartman, and I'm your Director of Investor Relations. Today, our CEO, Edward Haeggstrom; Chief Quality Officer, Johanna Kause; CFO, Albert Haeggstrom; Chief Commercial Officer, Christian Jones; and Chief Development Officer, Peter Hanninen, will present to you.
This presentation is webcasted through investor call, and there is also the possibility to call in and listen by phone. The slides shown here are also to be found on our web page in the Investors section. After the presentation, we will hold a Q&A and it's possible to ask questions by calling in. We will today start with a short introduction, then key business highlights, then financials, then commercial performance, and we conclude with our product kernels.
With
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
